Binnopharm Group, one of Russia’s leading pharmaceutical companies, announced a successful placement of its second bond issue in the current year. The amount of issued bonds was equal to 6 billion rubles, which confirms the high level of confidence in the company on the part of investors.

The maximum coupon rate on the bonds is set at 23.5%. The bond issue terms were developed taking into account the current market conditions and the interests of investors. This ensured high demand for the securities and significant oversubscription.

The Expert RA rating agency expectedly assigned ruA(EXP) credit rating to series 001P-05 bonds, which is an indicator of the company’s good financial standing and the ability to fulfil its obligations to investors.

Khafiz Gafurov, Chief Financial Officer of Binnopharm Group: «The successful placement of our second bond issue of the year demonstrates the confidence which the market has in Binnopharm Group as a reliable issuer. We see significant interest on the part of investors, as confirmed by this year’s first issue, which was placed with oversubscription. The placement of bonds was yet another step in the implementation of the company’s financial strategy aimed at maintaining sustainable growth and optimising our loan portfolio during a period of changes in the bank lending market».

Interest in the second issue of Binnopharm securities demonstrated by the market is attributable not only to the company’s stability, but also to the active role it plays in the Russian pharmaceutical market and its consistent development outside the country. The company continues to strengthen its position by investing in up-to-date projects, improving production facilities, conducting research and bringing high-quality and in-demand pharmaceutical products to the market.